Literature DB >> 314775

Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

H C Neu, K P Fu, N Aswapokee, P Aswapokee, K Kung.   

Abstract

The in vitro activity and beta-lactamase stability of 7-[d(-)-alpha-(4-ethyl-2,3-dioxopiperazino-carbonylamino) -p-hydroxyphenylacetamido]-3-[(1-methyl)-5-tetrazolylthiomethyl] -Delta(3)-cephem-4-carboxylic acid (cefoperazone), a cephalosporin analog of piperacillin, were compared with the activities and stabilities of other cephalosporins and cephamycins. The compound was less active than cephalothin or cefamandole in inhibiting Staphylococcus aureus; it was as active as cefamandole and cefoxitin against most of the Enterobacteriaceae but less active than cefotaxime. It was more active than carbenicillin or piperacillin against Pseudomonas aeruginosa. In general, the compound was not active against Bacteroides. It was hydrolyzed by the beta-lactamases of some Escherichia coli which hydrolyzed cefamandole, but was stable to most plasmid-mediated, chromosomally mediated, inducible beta-lactamases in the Enterobacteriaceae and Pseudomonas.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 314775      PMCID: PMC352812          DOI: 10.1128/AAC.16.2.150

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

Review 2.  The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors:  R B Sykes; M Matthew
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

3.  Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

4.  Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1974-08       Impact factor: 5.191

5.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

6.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

7.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

8.  Studies on gonococcus infection. XI. Comparison of in vivo and vitro association of Neisseria gonorrhoeae with human neutrophils.

Authors:  G King; J F James; J Swanson
Journal:  J Infect Dis       Date:  1978-01       Impact factor: 5.226

  8 in total
  61 in total

1.  In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.

Authors:  R J Fass; W W Gregory; R F D'Amato; J M Matsen; D N Wright; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.

Authors:  D P Reitberg; T J Whall; M Chung; D Blickens; H Swarz; J Arnold
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

3.  Ceftizoxime (FK 749) in vitro antibacterial activity.

Authors:  M O Husson; R Courcol; D Izard; H Leclerc
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

4.  Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.

Authors:  D P Reitberg; D A Marble; R W Schultz; T J Whall; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  In vitro and in vivo antibacterial activities of BO-1341, a new antipseudomonal cephalosporin.

Authors:  S Nakagawa; M Sanada; K Matsuda; T Hashizume; Y Asahi; R Ushijima; N Ohtake; N Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  In vitro activity of U-63196E, a new cephalosporin, against clinical bacterial isolates.

Authors:  G M Eliopoulos; A Gardella; P DeGirolami; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

8.  Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

9.  BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors:  B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

10.  In vitro evaluation of pyridine-2-azo-p-dimethylaniline cephalosporin, a new diagnostic chromogenic reagent, and comparison with nitrocefin, cephacetrile, and other beta-lactam compounds.

Authors:  R N Jones; H W Wilson; W J Novick
Journal:  J Clin Microbiol       Date:  1982-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.